Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Whellan, David

< Back

Profile

djw150

David J. Whellan, MD, MHS, FACC, FAHA

Contact Dr. Whellan

1015 Chestnut Street
Suite 317
Philadelphia, PA 19107

(215) 955-2636
(215) 503-7420 fax

Medical School

MD, Washington University School of Medicine
Master Health Science in Clinical Research, Duke University

Residency

Hospital of University of Pennsylvania (HUP)

Fellowship

Clinical Cardiology, Duke University Medical Center

Board Certification

Internal Medicine
Cardiovascular Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Interests

Dr. Whellan is the Principal Investigator of Jefferson Regional Clinical Center for the NIH HF Network, one of 9 centers across the United States selected to participate in a series of novel heart failure clinical trials. In addition, he serves as the Associate Provost for Clinical Research at Thomas Jefferson University and Associate Dean for Clinical Research at Sidney Kimmel Medical College.

He has authored over 175 peer-reviewed articles, reviews, abstracts, and book chapters on cardiomyopathy; and is an associate editor for the Journal of the American College of Cardiology Heart Failure journal.

Publications

Most Recent Peer-Reviewed Publications

  1. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency the IRONOUT HF randomized clinical trial
  2. A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study
  3. Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation
  4. Cognitive Outcomes After Coronary Artery Bypass Grafting
  5. Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial
  6. Cardiovascular Outcomes With Minute Ventilation–Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial
  7. Easy to Predict, Difficult to Prevent
  8. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?
  9. Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale
  10. Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes
  11. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke
  12. Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION)
  13. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial
  14. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers
  15. Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION
  16. Trends in Robotic-Assisted Coronary Artery Bypass Grafts: A Study of the Society of Thoracic Surgeons Adult Cardiac Surgery Database, 2006 to 2012
  17. Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial
  18. Comparison of Frequency of Frailty and Severely Impaired Physical Function in Patients ≥60 Years Hospitalized with Acute Decompensated Heart Failure Versus Chronic Stable Heart Failure with Reduced and Preserved Left Ventricular Ejection Fraction
  19. Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial
  20. Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk